Mediastinoscopic extended thymectomy for pediatric patients with myasthenia gravis

N Kitagawa1, M Shinkai1, H Take1

  • 1Department of Surgery, Kanagawa Children's Medical Center, Yokohama, Japan.

Insights

Mediastinoscopic extended thymectomy (MET) in children with myasthenia gravis (MG) offers good surgical access and cosmetic results. This technique led to remission or steroid dose reduction in most patients, with minimal complications.

Area of Science:

  • Pediatric Surgery
  • Neurology
  • Thoracic Surgery

Background:

  • Myasthenia gravis (MG) in children often requires extended thymectomy for drug-resistant or dependent cases.
  • Mediastinoscopic extended thymectomy (MET) is a surgical technique employed for pediatric MG.
  • This study focuses on the application and outcomes of MET in a pediatric cohort.

Purpose of the Study:

  • To evaluate the efficacy and safety of mediastinoscopic extended thymectomy (MET) in children with myasthenia gravis (MG).
  • To assess surgical outcomes, including operative time, blood loss, and postoperative complications.
  • To determine the long-term impact of MET on disease remission and medication requirements in pediatric MG patients.

Main Methods:

  • A cohort of 14 children with MG underwent MET between 2005 and 2013.
  • A V-shaped hook was used to create an infrasternal mediastinal field for thymus and surrounding adipose tissue extirpation.
  • Surgical parameters and postoperative outcomes were meticulously recorded.

Main Results:

  • The mean operative time was 182±44 minutes with an average blood loss of 34±43 ml.
  • Two patients experienced transient paralysis of the right recurrent nerve; the median hospital stay was 4.5 days.
  • Complete remission was achieved in 6 patients, 7 showed steroid dose reduction, and 1 had no improvement post-MET.

Conclusions:

  • MET provides excellent surgical access for bilateral phrenic nerve dissection during extended total thymectomy in children.
  • The procedure yields favorable cosmetic outcomes.
  • MET is an effective treatment option for pediatric myasthenia gravis, leading to significant clinical improvement in the majority of cases.
Abstract